

[New Drug Approvals](#)

Generic Name (Trade Name—Company)

October 18, 2018

Inotersen

(Tegsedi—Akcea Therapeutics and Ionis Pharma)

Agent targets polyneuropathy of hATTR in adults

Uses/Notes

Akcea Therapeutics and Ionis Pharma [announced](#) FDA approval of inotersen for treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults. It reduces the production of transthyretin (TTR) protein through a once-weekly S.C. injection. In hATTR amyloidosis, TTR protein misfolds and accumulates as amyloid deposits throughout the body.

FDA's approval of inotersen was based on results from the Phase III NEURO-TTR study in patients with hATTR amyloidosis with symptoms of polyneuropathy.

Results demonstrated that patients treated with inotersen experienced significant benefit compared with patients treated with placebo across both coprimary endpoints: the Norfolk Quality of Life Questionnaire–Diabetic Neuropathy and modified Neuropathy Impairment Score +7, a measure of neuropathic disease progression.

Inotersen is associated with risk of thrombocytopenia and glomerulonephritis. Enhanced monitoring is required to support early detection and management of these identified risks. For full prescribing information, including a boxed warning, please visit www.TEGSEDI.com. Inotersen is being marketed with a Risk Evaluation and Mitigation Strategy (REMS).

The most common adverse effects include injection-site reactions (such as redness or pain at the injection site), nausea, headache, tiredness, low platelet counts, and fever.

Source URL:

<http://www.aphanet.org/new-drug-approvals/agent-targets-polyneuropathy-hattr-adults>

A^{PhA} DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in A^{PhA} DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of A^{PhA}. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in A^{PhA} DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged

to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.